HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock Price, Quote, News and Overview
NASDAQ:HRMY - Nasdaq - US4131971040 - Common Stock
HRMY Quote and Key Statistics
HARMONY BIOSCIENCES HOLDINGS
NASDAQ:HRMY (1/21/2025, 4:53:55 PM)
Premarket: 42 +1.54 (+3.81%)40.46
+1.41 (+3.61%)
HRMY Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.98% | ||
| ROA | 13.21% | ||
| ROE | 20.55% | ||
| Debt/Equity | 0.28 |
HRMY Performance and Technical Analysis
HRMY Ownership and Analysts
HRMY Latest News and Analysis
Investors should take note of NASDAQ:HRMY, a growth stock that remains attractively priced.
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—a stock with solid growth prospects and a reasonable valuation.
Don't overlook NASDAQ:HRMY—it's a hidden gem with strong fundamentals and an attractive price tag.
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), an undervalued stock with good fundamentals.
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels.
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Some companies saw their shares skyrocket on preliminary reports, but others took hits.
Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
About HRMY
Company Profile
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 246 full-time employees. The company went IPO on 2020-08-19. The company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. The company also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. The company also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. The company is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
Company Info
HARMONY BIOSCIENCES HOLDINGS
630 W Germantown Pike, Suite 215
Plymouth Meeting PENNSYLVANIA 19462 US
CEO: John C. Jacobs
Employees: 246
Company Website: https://www.harmonybiosciences.com/
Investor Relations: https://ir.harmonybiosciences.com/
Phone: 14845399800
HRMY Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 72.99 | 704.73B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.38 | 359.88B | ||
| JNJ | JOHNSON & JOHNSON | 14.47 | 356.69B | ||
| MRK | MERCK & CO. INC. | 16.17 | 243.45B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.84 | 210.75B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.37 | 199.39B | ||
| PFE | PFIZER INC | 10.33 | 150.97B | ||
| SNY | SANOFI-ADR | 12.43 | 129.60B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.75 | 115.69B | ||
| ZTS | ZOETIS INC | 29.09 | 75.58B | ||
| GSK | GSK PLC-SPON ADR | 8.26 | 68.92B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.83 | 41.53B |